Immix Biopharma, Inc.
IMMX
$10.97
$0.050.46%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -74.51% | -122.05% | -122.10% | -6.10% | -50.76% |
| Total Depreciation and Amortization | 64.04% | 120.95% | 119.37% | 420.85% | 228.40% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 76.53% | -31.01% | -19.12% | -35.88% | -14.83% |
| Change in Net Operating Assets | -278.22% | -124.37% | -138.75% | -54.34% | 146.33% |
| Cash from Operations | -121.02% | -483.18% | -647.16% | -46.32% | -1.02% |
| Capital Expenditure | 83.54% | 51.99% | 67.45% | -37.20% | -31.41% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 2,192.24% | -6,991.29% | -1,210.33% | -37.20% | -31.41% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 13,881.79% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 13,888.20% | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -43.99% | -60.00% | 53.39% | -189.57% | 395.51% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,514.31% | -733.57% | 3,982.56% | 200.58% | 19.85% |